British American Tobacco's 13% Upside Isn't Enough for a Stock With This Much Risk

BAT's upside has narrowed after the rebound

BAT may still be undervalued, but the buffer is no longer especially wide. The latest model implies potential upside of 12.60%, based on an average target price of 5,145.83 GBp. After a sharp rebound, that gap looks less like a free lunch and more like a starting point.

That context matters. BAT is already up 11.6% year to date and 43.0% over the past year. Bulls can still point to a 4 out of 6 valuation score, but bears will argue the same point: investors may be treating cheap tobacco cash flows as a bargain when they are simply the market's answer to a structurally challenged business.

That is why timing matters now. A roughly 13% upside is not much reward once you factor in another regulatory shock, another ESG headline, or another shift in sentiment. If the market stays focused on the "deep value" label, the stock can still grind higher. But the margin for error is no longer large.

The bull case rests on a transition that still needs proof

That earlier rerating already reflects part of the "transition success" story. What bulls are betting on now is more specific: not just survival, but a meaningful shift in the earnings mix.

What the bull case actually is

Bulls are not buying BAT for legacy cigarette volume alone. They are buying the idea that Modern Oral and Vapour can cushion decline, improve earnings quality, and keep the cash engine intact. Management is explicitly saying the company is on track to deliver full-year guidance, with strong U.S. revenue and profit growth supported by combustibles, Vapour, and Modern Oral. That matters because the U.S. is the clearest proof point that the strategy has operating substance, not just narrative substance.

The clearest bull argument is the shift in category mix. BAT expects new-category revenue growth in the mid-teens for H1 and the full year, led by Modern Oral and a recovering Vapour business. If that momentum continues, investors can start to value BAT less as a declining cigarette name and more as a broader nicotine platform. Management is also confident in its mid-term targets: 3% to 5% revenue growth, 4% to 6% adjusted profit from operations, and 5% to 8% adjusted diluted EPS growth, with 2026 expected at the lower end of those ranges.

Where optimism can outrun the evidence

The risk is that investors anchor too quickly on one clean quarter and start treating temporary advantages as the new normal. That is where confirmation bias gets dangerous. It is easy to focus on Modern Oral as the fastest-growing new category and on VELO gaining share, while underestimating the parts of the business that still need support.

Even with that new-category momentum, BAT still faces a low double-digit revenue decline in heated products. That is not a side issue. It shows how uneven the transition really is. Modern Oral can look strong on its own, but it has not fully offset softer pockets elsewhere.

So the key analytical line is this: even if the transition works, BAT only becomes truly compelling if the market keeps narrowing the discount assigned to its structural risks. The market does not need to turn euphoric. It just needs to treat new-category wins as more durable rather than treating each one as a temporary bright spot.

If those operating gains keep improving, the stock can rerate again. If they stall, the bull case remains possible, but it is still more of a bridge than full validation.

Why the risk premium should still stay high

Bulls have real operating momentum, but that momentum can become a blind spot once a stock has already rerated. Management is on track to deliver full-year guidance, and the market can easily mistake that for proof of durability. The behavioral risk is recency bias: investors can start treating today's U.S. strength and favorable comparators as the baseline, while pushing future regulation, policy reversals, and category erosion into a too-neat "already priced in" bucket.

What the market may still be underpricing

The cleaner opportunity is not simply chasing another round of consensus upside. It is judging whether balance-sheet improvement and cash returns are strong enough to justify a lasting squeeze on the discount.

BAT is targeting 2.0x to 2.5x net debt to EBITDA by year-end and has a £1.3bn share buyback program in place. If those gains land while new-category revenue keeps growing at a strong pace, EPS quality can improve in a way the market cannot keep ignoring. But even that would still be conditional. Investors should not assume current execution automatically protects the business from the next policy shock.

That is why ESG and regulation still belong in the core model, not in a separate sentiment drawer. Management still reports through its Combined Annual and ESG report framework, which keeps those risks visible. Bears will also point to issues such as Firmly on track to deliver FY guidance, driven by continued U.S. delivery and New Category momentum and other regional or regulatory shifts as reminders that geography, product mix, and policy can still disrupt the story quickly.

What matters next

Watch the next quarter for proof of durability, not just momentum:

• Bullish confirmation: leverage moves toward target, cash returns hold up, and new-category growth remains healthy.
• What breaks the thesis: leverage stalls, new-category momentum fades, or fresh regulation hits before the portfolio diversifies further.

For now, the cleaner stance is still watch, don't chase. The recent rally already priced in some of the turnaround, and the next upside move likely belongs to verified durability rather than confident guidance alone.